Pegozafermin

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

Comparative efficacy of pharmacologic therapies for MASLD in improving fibrosis: systematic review and network meta-analysis.

Han X, Ai X, Sun Y et al.

Clinical Utility of a 50% and 30% Decline in Magnetic Resonance Imaging-Proton Density Fat Fraction in Predicting Fibrosis Improvement in Metabolic Dysfunction-associated Steatohepatitis.

Loomba R, Daniel PCN, Wang Y et al.

Efficacy and safety of fibroblast growth factor 21 analogs in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and network meta-analysis.

Abdeljawad MM, Hasan MT, Fareed A et al.